Microcystic lymphatic malformation (MLM), also known as "lymphangioma circumscriptum," is a lymphatic malformation which may involve the skin and subcutaneous tissues. Progressive growth of lesions may cause pressure to the surrounding organs. Lesions frequently reoccur after treatment with surgery, sclerotherapy, radiotherapy, and laser therapy. In the last decades, oral sirolimus has been successfully used in lymphatic malformations. Since systemic treatment with sirolimus is associated with various side effects, topical form of the drug has been used with satisfying results, especially for the angiofibromas. Promisingly, few case studies indicate topical sirolimus as a potential treatment for the lymphatic malformations. Here, we report an 8-year-old girl with MLM on left trunk whose lesions recurred after the surgery that has been performed at 1 year of age. We administered twice daily topical sirolimus at 0.75 mg/ml concentration. After 2 weeks, a local irritation occurred and the dose was decreased to once daily. The treatment was stopped at the end of 3 months as the lesions were almost cleared and the patient did not want to continue to therapy. There were no new lesions after 8 months of follow up.

Levetiracetam (LEV) is an established second generation anti-epileptic drug and LEV associated severe cutaneous reactions are rare. Here we report the case of psoriasiform drug eruption in a patient with newly diagnosed epilepsy who had been treated with levetiracetam. To our knowledge this is the first report of a patient with a psoriasiform eruption that appeared after the administration of LEV.

No abstract

Alopecia has a significant negative impact on the quality of life. Unfortunately, there is no satisfactory cure for most types of alopecia. Alopecia is divided into cicatricial and noncicatricial types. Androgenetic alopecia, alopecia areata, and telogen effluvium are common forms of noncicatricial alopecias. In order to treat or improve the appearance, various procedures that are being applied for different types of alopecia including mesotherapy, microneedling, platelet-rich plasma, low-level light therapy, and stem-cell therapy with variable outcomes are reviewed in this chapter.

No abstract

No abstract

Background and Design:Behçet's disease (BD) is a chronic inflammatory disorder. Genetic susceptibility, triggering infections and environmental factors that alter innate and acquired immunity are accused in its pathogenesis. Visfatin is a novel adipocytokine which exerts proinflammatory effects. In the present study, by comparing serum visfatin levels in patients with active BD with those in patients with inactive BD and healthy controls, we investigated the role of visfatin in the inflammatory process of BD. Materials and Methods:We enrolled 26 patients with active BD, 26 with inactive BD and 26 healthy controls in the study. Serum visfatin levels were analyzed by an enzyme-linked immunosorbent assay. White blood cell (WBC) count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and interleukin-6 (IL-6) levels were measured simultaneously and their correlation with visfatin levels were examined. Results: Age and gender distributions did not differ between the study groups (p=0.736 and p=1.00, respectively). Serum visfatin levels were significantly higher in patients with active BD (17.80±5.70 ng/mL) and inactive BD (12.80±2.90 ng/mL) than in controls (8.90±4.20 ng/mL), (p=0.00 for both comparisons). Active BD patients had significantly higher visfatin levels when compared to inactive BD patients (p=0.00). In all study groups, visfatin levels were positively correlated with WBC count, ESH, CRP, and IL-6 levels. Conclusion: Our results support the idea that visfatin plays a role in the inflammatory process of BD and suggest that visfatin may be a novel activity marker in BD. (Turkderm 2014; 48: 82-6)

No abstract